Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
S Lindsey DavisAnastasia A IonkinaStacey M BagbyJames D OrthBrian GittlemanJoshua M MarcusElaine T LamBradley R CorrCindy L O'BryantAshley E GlodeAik-Choon TanJihye KimJohn J TentlerAnna CapassoKyrie L LopezDaniel L GustafsonWells A MessersmithStephen LeongS Gail EckhardtTodd M PittsJennifer R DiamondPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The addition of TAK-228 to alisertib potentiates the antitumor activity of alisertib in vivo, resulting in increased cell death and apoptosis. The combination is tolerable in patients with advanced solid tumors and should be evaluated further in expansion cohorts with additional pharmacodynamic assessment.